Clinical Trial Update: Alternative Treatment Paradigm for Natalizumab Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating natalizumab for multiple sclerosis has been withdrawn. The sponsor indicates the study is no longer active.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Natalizumab (Tysabri) (Natalizumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Multiple Sclerosis (MS) | Phase 2 | Status: WITHDRAWN